Welcome to our dedicated page for Coya Therapeutics SEC filings (Ticker: COYA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Coya Therapeutics, Inc. (NASDAQ: COYA) SEC filings page provides access to the company’s U.S. Securities and Exchange Commission disclosures, which document its status as a Nasdaq-listed clinical-stage biotechnology company and outline key corporate, financing, and clinical development events. Coya’s common stock, par value $0.0001 per share, is registered under Section 12(b) of the Exchange Act and trades on The Nasdaq Stock Market LLC under the symbol COYA, as noted in multiple Form 8-K filings.
In its recent current reports on Form 8-K, Coya has disclosed material events such as milestone payments received under a Development and License Agreement with Dr. Reddy’s Laboratories Ltd. tied to FDA acceptance of an Investigational New Drug (IND) application for COYA 302 in amyotrophic lateral sclerosis (ALS) and dosing of the first patient in the Phase 2 ALSTARS Trial. Other 8-K filings describe the submission and resubmission of the IND for COYA 302, FDA review timelines, and acceptance of a Clinical Trial Application (CTA) by Health Canada.
Filings also cover capital markets activity, including an Underwriting Agreement for an underwritten public offering of common stock and related details such as the number of shares offered, offering price, estimated gross proceeds, and issuance of warrants to a financial advisor. Additional 8-Ks report quarterly financial results via furnished press releases, as well as outcomes of the company’s annual meeting of stockholders, including director elections and auditor ratification.
On Stock Titan, Coya’s SEC filings are updated as new documents are posted to EDGAR. Users can review 8-Ks related to clinical milestones, financing transactions, and governance matters, alongside other periodic and registration statements, while AI-powered tools help summarize key points and highlight items such as trial progress, milestone payments, and changes affecting COYA shareholders.
Coya Therapeutics, Inc. announced a planned board transition in which founder Howard Berman, Ph.D., resigned as Executive Chairman and director effective April 1, 2026, under a Separation and General Release Agreement that provides a prorated 2026 bonus, COBRA premium coverage and extended stock option vesting and exercise periods.
The board appointed biopharmaceutical executive Mark H. Pavao as an independent Class III director, effective April 1, 2026, with a term running to the 2028 annual meeting and a grant of options to purchase 10,000 shares vesting after one year, alongside standard non‑employee director compensation.
Coya Therapeutics files a resale prospectus to register 2,522,727 shares of common stock for resale by selling stockholders. The registration covers 2,522,727 shares issued in a private placement on January 30, 2026 and states the Company will not receive any proceeds from resales.
The prospectus notes 23,457,183 shares outstanding as of March 10, 2026 and discloses a Nasdaq last sale price of $4.27 on March 19, 2026. The registration permits the selling stockholders to sell shares in various manners described under the Plan of Distribution.
Coya Therapeutics, Inc. registers for resale 2,522,727 shares of common stock issued in a January 29, 2026 private placement. The prospectus states these Shares were issued in the Private Placement at $4.40 per share and that the Company will receive no proceeds from resales by the selling stockholders.
The filing lists selling holders (including Greenlight Capital and Dr. Reddy’s), describes allowable methods of resale, and confirms the Company will pay registration expenses. Shares outstanding were 23,457,183 as of March 10, 2026.
Coya Therapeutics, Inc. is a clinical-stage biotech focused on therapies that enhance regulatory T cells to treat neurodegenerative, autoimmune and metabolic diseases. Its lead biologic, COYA 302, is in a Phase 2 ALSTARS trial for ALS after FDA IND acceptance, with an additional IND cleared for frontotemporal dementia. The company is also advancing COYA 303 and the low-dose IL-2 backbone COYA 301, plus Treg-derived exosome programs.
Coya reported a 2025 net loss of $21.2 million, up from $14.9 million in 2024, and an accumulated deficit of $62.0 million as of December 31, 2025. In January 2026 it raised $11.1 million in gross proceeds, including $10 million from strategic collaborator Dr. Reddy's, and expects its cash runway to extend into the second half of 2027. Management nonetheless states it will need substantial additional capital and highlights going-concern uncertainty if funding is not obtained.
Coya Therapeutics reported full-year 2025 results alongside a broad corporate update. Collaboration revenue rose to $7.9M from $3.6M, mainly from $6.7M of license milestones tied to its COYA 302 ALS program. Operating expenses increased to $30.5M, driven by higher clinical and R&D spending and greater general and administrative costs.
Net loss widened to $21.2M from $14.9M, reflecting heavier investment in development. Cash and cash equivalents were $46.8M at year-end. The company completed a $23.0M upsized public offering and an $11.1M private placement, extending its stated cash runway into the second half of 2027.
Coya advanced COYA 302 into the ALSTARS Phase 2 ALS trial across roughly 25 sites in the U.S. and Canada, received FDA and Health Canada clearances for new indications, and reported supportive translational and preclinical data for COYA 302 and COYA 303. Multiple clinical and publication milestones are targeted through 2026.
Dr. Reddy's Laboratories reported beneficial ownership of 2,272,727 shares of Coya Therapeutics, Inc. common stock, representing 9.7% of the class. The shares are directly held by Dr. Reddy's Laboratories, Inc.; Dr. Reddy's Laboratories SA and Dr. Reddy's Laboratories Limited are disclosed as potentially deemed beneficial owners through the corporate chain.
The filing cites 20,924,456 shares outstanding as of November 10, 2025 and 2,522,727 shares issued and outstanding as of January 29, 2026 in related issuer reports; the ownership table shows sole voting and dispositive power for the 2,272,727 shares.
The Vanguard Group reported beneficial ownership of 899,140 shares of Coya Therapeutics Inc common stock, representing 4.29% of the class as of December 31, 2025. Vanguard has shared voting power over 117,776 shares and shared dispositive power over all 899,140 shares, with no sole voting or dispositive power.
The shares are held for Vanguard’s clients, who have rights to dividends and sale proceeds, and no single other person has more than 5% interest in these securities. Vanguard notes an internal realignment on January 12, 2026, after which certain subsidiaries may report beneficial ownership separately while pursuing the same investment strategies.
Coya Therapeutics, Inc. entered into a securities purchase agreement for a private placement of 2,522,727 common shares at $4.40 per share, raising approximately $11.1 million in gross proceeds. The investors are Dr. Reddy’s Labs, contributing $10.0 million, and Greenlight Capital, an existing institutional stockholder, contributing $1.1 million.
The company plans to use the net proceeds to transfer and scale manufacturing of low dose IL‑2 and accelerate manufacturing programs needed for commercial readiness of COYA 302. Management states these funds are expected to support accelerated commercial readiness plans while reiterating cash runway guidance into the second half of 2027 and past the projected topline for the ALSTARS trial.
Coya Therapeutics, Inc. received an updated ownership report on its common stock from investor Orin Hirschman and affiliated entities on a Schedule 13G/A (Amendment No. 3).
Mr. Hirschman reports beneficial ownership of 1,108,171 shares, representing 5.3% of Coya’s common stock, with sole voting and dispositive power over these shares. AIGH Capital Management LLC reports beneficial ownership of 975,404 shares, representing 4.7% of the class, also with sole voting and dispositive power. The filing is made on a passive basis, stating the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Coya Therapeutics.